Essential medicines for COPD and asthma in low and middle-income countries

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Access to medications for chronic disease management is limited in many low and middle-income countries (LMICs), resulting in suboptimal care and avoidable morbidity and mortality. We performed a survey of COPD and asthma medicines that appeared on the national essential medicines lists (NEMLs) of 32 LMICs. Nearly all countries (>90%) had assigned essential medicines for treatment of exacerbations and early stable disease stages, but not for steps 4 (22%) and 5 (6%) controlled asthma management. The number of treatment options was limited, with long-acting β2-agonists (LABA) and combination dosage forms being notably absent. Suboptimal availability of chronic respiratory disease medicines suggests that implementation of NEMLs is the main problem in clinical practice.

Original languageEnglish
Pages (from-to)1149-51
Number of pages3
JournalThorax
Volume69
Issue number12
DOIs
Publication statusPublished - Dec 2014

Fingerprint

Dive into the research topics of 'Essential medicines for COPD and asthma in low and middle-income countries'. Together they form a unique fingerprint.

Cite this